EGFR and non-small cell lung carcinoma: A proteomic study in non-small-cell lung cancer cells identified CK2 as a central element to mediate TKI resistance, and the phosphorylation of its substrate HMGA1 as a critical node to promote resistance to the EGFR inhibitor gefitinib [25].